Pfizer Inc. Stock
€23.16
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 0.500% | -2.145% | -1.222% | 15.860% | 8.271% | -38.560% | -26.613% |
| BioMarin Pharmaceutical Inc. | 0.660% | -4.486% | -8.551% | -11.955% | -7.976% | -47.371% | -28.815% |
| Johnson & Johnson | -0.370% | -2.248% | -4.216% | 48.480% | 14.405% | 33.907% | 50.918% |
| Biogen Inc. | -0.410% | -0.791% | -3.695% | 47.522% | 2.089% | -41.611% | -32.280% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
What to Look for Before Buying a Pharma Stock
There are many criteria for evaluating a pharmaceutical stock, but one of the easiest to start with is the drug pipeline. You can do so by looking at quarterly reports or listening to earnings
Better Buy Right Now: Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors.
One of those sectors may be
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe?
Although high dividend yields are attractive to income seekers, they can sometimes signal that the dividend is unsustainable and a payout cut is on the way. Is that where we are headed with Pfizer